Niagen Bioscience, Inc. (NAGE) stock
NAGENasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3011% below fair value
$1.94−0.10 (-4.90%)
Close on Nov 18, 2026Market cap $153.50MP/E 16.2Yield –
Niagen Bioscience operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Niagen Bioscience's operating income for the twelve months ending Sep 30, 2026 was $4.78M, down 75.3% year over year. For fiscal 2025 it was $16.28M, up 110.7% from the year before. The highest annual figure on record is $16.28M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.28M | +110.7% |
| FY2024 | Dec 31, 2024 | $7.73M | – |
| FY2023 | Dec 31, 2023 | -$5.60M | – |
| FY2022 | Dec 31, 2022 | -$18.63M | – |
| FY2021 | Dec 31, 2021 | -$27.07M | – |
| FY2020 | Dec 31, 2020 | -$19.85M | – |
| FY2019 | Dec 31, 2019 | -$31.30M | – |
| FY2018 | Dec 31, 2018 | -$33.17M | – |
| FY2017 | Dec 30, 2017 | -$16.38M | – |
| FY2016 | Dec 31, 2016 | -$2.91M | – |
| FY2015 | Jan 2, 2016 | -$2.07M | – |
| FY2014 | Jan 3, 2015 | -$5.23M | – |
| FY2013 | Dec 28, 2013 | -$4.39M | – |
| FY2012 | Dec 29, 2012 | -$11.64M | – |
| FY2011 | Dec 31, 2011 | -$7.86M | – |
| FY2010 | Jan 1, 2011 | -$2.02M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$1.59M | -137.5% |
| Q2 FY2026 | Jun 30, 2026 | $700.00K | -78.0% |
| Q1 FY2026 | Mar 31, 2026 | $1.58M | -67.0% |
| Q4 FY2025 | Dec 31, 2025 | $4.09M | -42.5% |
| Q3 FY2025 | Sep 30, 2025 | $4.24M | +164.4% |
| Q2 FY2025 | Jun 30, 2025 | $3.19M | – |
| Q1 FY2025 | Mar 31, 2025 | $4.77M | – |
| Q4 FY2024 | Dec 31, 2024 | $7.11M | – |
| Q3 FY2024 | Sep 30, 2024 | $1.60M | – |
| Q2 FY2024 | Jun 30, 2024 | -$256.00K | – |
| Q1 FY2024 | Mar 31, 2024 | -$731.00K | – |
| Q4 FY2023 | Dec 31, 2023 | -$168.00K | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.15M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.32M | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.97M | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.44M | – |
| Q3 FY2022 | Sep 30, 2022 | -$3.07M | – |
| Q2 FY2022 | Jun 30, 2022 | -$6.39M | – |
| Q1 FY2022 | Mar 31, 2022 | -$7.73M | – |
| Q4 FY2021 | Dec 31, 2021 | -$5.32M | – |
| Q3 FY2021 | Sep 30, 2021 | -$8.84M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.55M | – |
| Q1 FY2021 | Mar 31, 2021 | -$7.36M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.08M | – |
| Q3 FY2020 | Sep 30, 2020 | -$4.20M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.69M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.89M | – |
| Q4 FY2019 | Dec 31, 2019 | -$8.86M | – |
| Q3 FY2019 | Sep 30, 2019 | -$6.89M | – |
| Q2 FY2019 | Jun 30, 2019 | -$7.18M | – |
| Q1 FY2019 | Mar 31, 2019 | -$8.37M | – |
| Q4 FY2018 | Dec 31, 2018 | -$8.24M | – |
| Q3 FY2018 | Sep 30, 2018 | -$8.60M | – |
| Q2 FY2018 | Jun 30, 2018 | -$7.94M | – |
| Q1 FY2018 | Mar 31, 2018 | -$8.40M | – |
| Q4 FY2017 | Dec 30, 2017 | -$8.78M | – |
| Q3 FY2017 | Sep 30, 2017 | -$3.18M | – |
| Q4 FY2016 | Dec 31, 2016 | -$2.17M | – |
| Q3 FY2016 | Oct 1, 2016 | -$924.16K | – |
See a number that looks wrong?